SDGR vs. GRFS, TLX, TGTX, NUVL, LEGN, LNTH, AXSM, ADMA, PCVX, and MRUS
Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), Legend Biotech (LEGN), Lantheus (LNTH), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Schrödinger vs. Its Competitors
Schrödinger (NASDAQ:SDGR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Schrödinger currently has a consensus target price of $32.80, indicating a potential upside of 22.89%. Given Schrödinger's higher possible upside, equities research analysts clearly believe Schrödinger is more favorable than Grifols.
Grifols received 296 more outperform votes than Schrödinger when rated by MarketBeat users. However, 58.33% of users gave Schrödinger an outperform vote while only 56.23% of users gave Grifols an outperform vote.
Grifols has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
79.1% of Schrödinger shares are owned by institutional investors. 8.6% of Schrödinger shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Schrödinger had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Schrödinger and 4 mentions for Grifols. Grifols' average media sentiment score of 1.08 beat Schrödinger's score of 0.56 indicating that Grifols is being referred to more favorably in the news media.
Grifols has a net margin of 0.00% compared to Schrödinger's net margin of -91.84%. Grifols' return on equity of 0.00% beat Schrödinger's return on equity.
Schrödinger has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Summary
Grifols beats Schrödinger on 10 of the 18 factors compared between the two stocks.
Get Schrödinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrödinger Competitors List
Related Companies and Tools
This page (NASDAQ:SDGR) was last updated on 6/12/2025 by MarketBeat.com Staff
